137 related articles for article (PubMed ID: 32503697)
1. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
6. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
[TBL] [Abstract][Full Text] [Related]
8. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
[TBL] [Abstract][Full Text] [Related]
10. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
12. Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
Zhuo LS; Wu FX; Wang MS; Xu HC; Yang FP; Tian YG; Zhao XE; Ming ZH; Zhu XL; Hao GF; Huang W
Eur J Med Chem; 2020 Dec; 208():112785. PubMed ID: 32898795
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.
Sun H; Zhuo L; Dong H; Huang W; She N
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817456
[TBL] [Abstract][Full Text] [Related]
14. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
15. Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
Liao W; Hu G; Guo Z; Sun D; Zhang L; Bu Y; Li Y; Liu Y; Gong P
Bioorg Med Chem; 2015 Aug; 23(15):4410-4422. PubMed ID: 26169763
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2.
Wei D; Fan H; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Zhang Q; Zeng C; Hu L
Bioorg Chem; 2019 Jul; 88():102916. PubMed ID: 31026719
[TBL] [Abstract][Full Text] [Related]
17. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
Wang X; Jiang N; Zhao S; Xi S; Wang J; Jing T; Zhang W; Guo M; Gong P; Zhai X
Bioorg Med Chem; 2017 Feb; 25(3):886-896. PubMed ID: 28011202
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
